Rebiotix: Ferring Presents Complete Data across Five RBX2660 Trials Demonstrating Consistent and Durable Efficacy in Recurrent C. Difficile Infection, as Well as Multiple Analyses Demonstrating Positive Shifts in Microbiome Properties

(marketscreener.com) Data from award-winning presentation at IDWeek 2021 represents the first time Ferring is showcasing the RBX2660 clinical development program as a whole, comprising the largest, most robust program ever conducted in the field of microbiome-based therapeutics for recurrent C. difficile infection Only gut microbiome research program with five...https://www.marketscreener.com/news/latest/Ferring-Presents-Complete-Data-across-Five-RBX2660-Trials-Demonstrating-Consistent-and-Durable-Effi--36549199/?utm_medium=RSS&utm_content=20210929